Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | PPARG | P37231 | 6/20 | 0.39 |
| ▸ | PPARD | Q03181 | 6/20 | 0.39 |
| ▸ | PPARA | Q07869 | 6/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11791107 | 1.00 | TSHR (0.46) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL7884128 | 1.00 | TSHR (0.46) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL1194865 | 1.00 | TSHR (0.46) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL23788019 | 1.00 | TSHR (0.46) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL1608462 | 1.00 | TSHR (0.46) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL23788184 | 1.00 | TSHR (0.46) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL9449787 | 1.00 | TSHR (0.46) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL8817428 | 0.98 | LMNA (0.44) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL5679801 | 0.98 | TSHR (0.48) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL8817917 | 0.96 | LMNA (0.46) | TSHRLMNANFKB1PMP22GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017216360-A1 | METABOLICALLY STABLE SPEXIN PEPTIDE ANALOGS | UNIVERSITÉ DE STRASBOURG (FR) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017216359-A1 | METABOLICALLY STABLE PEPTIDE ANALOGS | UNIVERSITÉ DE STRASBOURG (FR) | 2017-12-21 | — | — | WO | disclosed |
| EP-3257863-A1 | FLOUROUS METABOLICALLY STABLE PEPTIDE ANALOGS | Université de Strasbourg (FR) | 2017-12-20 | — | — | EP | disclosed |
| US-20170355734-A1 | Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor | UNIVERSITE DE STRASBOURG (FR) | 2017-12-14 | — | — | US | disclosed |
| EP-1740207-B1 | ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | IMMUNE TARGETING SYSTEMS ITS LTD (GB) | 2012-12-19 | — | — | EP | disclosed |
| US-8110540-B2 | Antigen delivery vectors and constructs | IMMUNE TARGETING SYSTEMS LTD. (GB) | 2012-02-07 | — | — | US | disclosed |
| US-8110541-B2 | Antigen delivery vectors and constructs | IMMUNE TARGETING SYSTEMS LTD. (GB) | 2012-02-07 | — | — | US | disclosed |
| US-20100183708-A1 | Antigen Delivery Vectors and Constructs | IMMUNE TARGETING SYSTEMS LTD. | 2010-07-22 | — | — | US | disclosed |
| US-20100183650-A1 | Antigen Delivery Vectors and Constructs | IMMUNE TARGETING SYSTEMS LTD. | 2010-07-22 | — | — | US | disclosed |
| US-7687455-B2 | comprising fluorocarbon vector-antigen, immunogens; vaccines, immunotherapy | IMMUNE TARGETING SYSTEMS LTD. (GB) | 2010-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183650-A1 | Antigen Delivery Vectors and Constructs | LY96, CD74, CD69 | TSHR 3438/4885LMNA 4002/4885NFKB1 681/4885 |
| US-20170355734-A1 | Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor | APLNR, AVPR2, AVPR1A | TSHR 297/4885LMNA 2310/4885NFKB1 2735/4885 |
| US-20100183708-A1 | Antigen Delivery Vectors and Constructs | LY96, CD74, CD69 | TSHR 3438/4885LMNA 4002/4885NFKB1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.